GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Central Pharmaceuticals Ltd (DHA:CENTRALPHL) » Definitions » Financial Strength

Central Pharmaceuticals (DHA:CENTRALPHL) Financial Strength : 3 (As of Sep. 2022)


View and export this data going back to 2013. Start your Free Trial

What is Central Pharmaceuticals Financial Strength?

Central Pharmaceuticals has the Financial Strength Rank of 3. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.

Warning Sign:

Central Pharmaceuticals Ltd displays poor financial strength. Usually, this is caused by too much debt for the company.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

Central Pharmaceuticals did not have earnings to cover the interest expense. Central Pharmaceuticals's debt to revenue ratio for the quarter that ended in Sep. 2022 was 10.74. As of today, Central Pharmaceuticals's Altman Z-Score is 1.53.


Competitive Comparison of Central Pharmaceuticals's Financial Strength

For the Drug Manufacturers - Specialty & Generic subindustry, Central Pharmaceuticals's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Central Pharmaceuticals's Financial Strength Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Central Pharmaceuticals's Financial Strength distribution charts can be found below:

* The bar in red indicates where Central Pharmaceuticals's Financial Strength falls into.



Central Pharmaceuticals Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Central Pharmaceuticals's Interest Expense for the months ended in Sep. 2022 was BDT-0.01 Mil. Its Operating Income for the months ended in Sep. 2022 was BDT-9.73 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was BDT231.98 Mil.

Central Pharmaceuticals's Interest Coverage for the quarter that ended in Sep. 2022 is

Central Pharmaceuticals did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Central Pharmaceuticals's Debt to Revenue Ratio for the quarter that ended in Sep. 2022 is

Debt to Revenue Ratio=Total Debt (Q: Sep. 2022 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(36.497 + 231.978) / 24.988
=10.74

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Central Pharmaceuticals has a Z-score of 1.53, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of 1.53 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Central Pharmaceuticals  (DHA:CENTRALPHL) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Central Pharmaceuticals has the Financial Strength Rank of 3. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.


Central Pharmaceuticals Financial Strength Related Terms

Thank you for viewing the detailed overview of Central Pharmaceuticals's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Central Pharmaceuticals (DHA:CENTRALPHL) Business Description

Traded in Other Exchanges
N/A
Address
South West Darus Salam Road, 2-A/1, 2nd Floor, Mirpur - 1, Dhaka, BGD, 1216
Central Pharmaceuticals Ltd is engaged in the manufacturing and marketing of medicines in Bangladesh. The company manufactures finished formulation products for general people, hospitals, clinics, government organizations, corporations, and other non-government organizations. Its product portfolio encompasses therapeutic categories including gastrointestinal, anti-infective, vitamins and minerals, allergy cough and cold, analgesic and musculoskeletal, dermatological, oral rehydration salt, and others. The products are in the dosage forms of tablets, capsules, liquid, and ointments.

Central Pharmaceuticals (DHA:CENTRALPHL) Headlines

No Headlines